Skip to main content
Equibles
CGON logo

CGON · CG Oncology, Inc. · Metrics

Track CGON — free

Use CGON with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CGON.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$62.24 +0.31 (+0.50%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Market Cap
$5.52B
Shares
88.64M
Volume · Oct 21 530.15K Avg daily vol (3M) 872.01K

CGON metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$62.24
Market cap
$5.52B

Price action

20 metrics
Price change (1W)
+0.6%
Price change (30D)
-19.9%
Price change (3M)
-10.2%
Price change (6M)
-10.9%
Price change (YTD)
+49.9%
Price change (1Y)
+44.5%
Trailing year
Price change (5Y)
—
52-week high
$80.68
52-week low
$37.37
Change from 52-week high
-22.9%
Change from 52-week low
+66.6%
Annualized volatility
55.9%
Annualized volatility (3M)
45.4%
Beta
1.1
RSI (14D)
38.5
Price vs SMA 50
-12.8%
Price vs SMA 200
-4.8%
Avg volume (3M)
872,014
Relative volume
0.6
Average dollar volume
$62.17M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
88.64M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
721.2×
reciprocal yield 0.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
885.8×
reciprocal yield 0.1%
P / book
5.4
reciprocal yield 18.7%
FCF yield
-3.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-4,056.2%
Trailing 12 months
Net margin
-3,602.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$252.62M
Net income (TTM)
−$224.38M
Trailing 12 months
Diluted EPS (TTM)
$-2.70
FCF margin
-2,879.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.08
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.04
EBITDA per diluted share (TTM)
$-3.00
Net income per diluted share (TTM)
$-2.70
Operating cash flow per diluted share (TTM)
$-2.16
Free cash flow per diluted share (TTM)
$-2.17
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.87
Stock compensation per diluted share (TTM)
$0.42
Book value per share
$9.33

Growth

11 metrics
Revenue growth YoY
+254.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$6.23M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-21.8%
Return on assets
-20.7%
Debt / equity
0.0
Current ratio
22.2
EBITDA (TTM)
−$249.66M
Free cash flow (TTM)
−$179.34M
Quick ratio
22.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.03B
Latest balance sheet
Cash & equivalents
$19.64M
Total assets
$1.09B
Total debt
$3.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$178.47M
Capital expenditures (TTM)
$876,000
R&D (TTM)
$156.23M
SG&A (TTM)
—
Stock compensation (TTM)
$35.33M
R&D / revenue
2,508.5%
Stock compensation / revenue
567.2%

Ownership (13F)

9 metrics
13F filers
235
13F filer change QoQ
-3
Institutional ownership
111.7%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.5%
Holder tenure
7.5
Price vs estimated holder cost
+62.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.6%

Short interest

3 metrics
Short interest
11.8%
Latest settlement · 8.5 days to cover
Days to cover
8.5d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$147,520
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1991792 CUSIP 156944100 13F (30d) 19 filings 19 filers Visit website Investor relations